Arthneeti
Unichem Laboratories Ltd Q2 FY27 results are out (Jul–Sep 2026) →Revenue ₹640 Cr +10.5% YoYSee revenue, profit and what management said. You are viewing Q4 FY17.
UL

Unichem Laboratories Ltd

Q4 FY17Pharmaceuticals & Biotechnology

Unichem Laboratories Q4 FY17 earnings call: Revenue & Margins

Q4 FY17 investor presentation: what the company reported on revenue, margins and capex.

Unichem Laboratories Ltd Q4 FY17 key numbers

Revenue
API revenue (Standalone basis): INR 11,852 lakhs for the quarter, up 18% YoY.

As stated in Unichem Laboratories Ltd's Q4 FY17 investor presentation · published 25 Sept 2026. Reported figures, not investment advice.

Based on Unichem Laboratories Ltd's Q4 FY17 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹553
Market cap₹3.8K Cr
P/E31.4

The short version

Quarter ended March 31, 2017 revenue from operations: INR 18,735 lakhs, up 7% YoY (from INR 17,447 lakhs in Q4 FY16) (Page 38). - API revenue (Standalone basis): INR 11,852 lakhs for the quarter, up 18% YoY (Page 38). - Total income for the quarter: INR 34,393 lakhs, up 13% YoY. - EBITDA margin for Q4 FY17 was 9.8% (Page 38). - Earning per share (EPS) Q4 FY17: INR 3.35, up 8% YoY (Page 38). - Quarter ended March 31, 2017 (Q4 FY17) Standalone Financials (INR Lakhs): - EBITDA: ₹3,146 Lakhs, 14% growth YoY - Operating Income (Operating Profit): ₹2,299 Lakhs, 9% growth YoY - Profit After Tax (PAT): ₹2,305 Lakhs, -14% decline YoY - Margins: - EBITDA margin: 9.1% for Q4 FY17, steady compared to 9.1% in Q4 FY16 - Operating margin: 7.3% for Q4 FY17, down from 8.3% in Q4 FY16 - PAT margin: approx.

From Unichem Laboratories Ltd's Q4 FY17 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Quarter ended March 31, 2017 revenue from operations: INR 18,735 lakhs, up 7% YoY (from INR 17,447 lakhs in Q4 FY16) (Page 38).
  • API revenue (Standalone basis): INR 11,852 lakhs for the quarter, up 18% YoY (Page 38).
  • Total income for the quarter: INR 34,393 lakhs, up 13% YoY.
  • EBITDA margin for Q4 FY17 was 9.8% (Page 38).

2 more points from Unichem Laboratories Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

Quarter ended March 31, 2017 (Q4 FY17) Standalone Financials (INR Lakhs):

Locked: what Unichem Laboratories Ltd said on margins

Also locked on this page: fundraising, order book

Free account, 30 seconds. No card needed.

Capital Expenditure Plans

  • SEZ Pithampur: Construction started (page 6).
  • Expansion at API facility in Pithampur: Commenced (page 6).
  • Acquisition of API facility in Kolhapur, Maharashtra (page 6).
  • Commissioned expanded capacities at Goa Formulation plant, significantly increasing capacities (page 6).
  • Realignment and further sub-divisionalization of Chronic business with increased focus on Chronic; launched new division on Cardio & Neuro (page 6).
  • Construction of R&D Centre at Goa started (2012) and relocation of R&D from Mumbai to Goa as Centre of Excellence, with filings commissioned from new R&D Centre (page 6).
  • Baddi II plant commissioned (2007-08).

2 more points from Unichem Laboratories Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1Ind-Swift Laboratories
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Unichem Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Unichem Laboratories Ltd said on order book & pipeline — free account, 30 seconds.

Unichem Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹640 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Unichem Laboratories's management said in earlier quarters

Earlier calls (2)

Others in Pharmaceuticals & Biotechnology this season

  • FDC (Q4 FY17)

    The year-on-year revenue growth for Q4 FY 2017 was 3.7%. Key concall takeaways from FDC Ltd's Q4 FY17 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Unichem Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Unichem Laboratories Ltd Q4 FY17 results?

Quarter ended March 31, 2017 revenue from operations: INR 18,735 lakhs, up 7% YoY (from INR 17,447 lakhs in Q4 FY16) (Page 38). - API revenue (Standalone basis): INR 11,852 lakhs for the quarter, up 18% YoY (Page 38). - Total income for the quarter: INR 34,393 lakhs, up 13% YoY. - EBITDA margin for Q4 FY17 was 9.8% (Page 38). - Earning per share (EPS) Q4 FY17: INR 3.35, up 8% YoY (Page 38). - Quarter ended March 31, 2017 (Q4 FY17) Standalone Financials (INR Lakhs): - EBITDA: ₹3,146 Lakhs, 14% growth YoY - Operating Income (Operating Profit): ₹2,299 Lakhs, 9% growth YoY - Profit After Tax (PAT): ₹2,305 Lakhs, -14% decline YoY - Margins: - EBITDA margin: 9.1% for Q4 FY17, steady compared to 9.1% in Q4 FY16 - Operating margin: 7.3% for Q4 FY17, down from 8.3% in Q4 FY16 - PAT margin: approx.

What is Unichem Laboratories Ltd share price analysis?

Unichem Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 31.4 with a market cap of ₹3,842 Cr. Investors should review the full earnings analysis for detailed insights.

Is Unichem Laboratories Ltd planning capital expenditure?

SEZ Pithampur: Construction started (page 6).

Keep Unichem Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.